BR0312615A - Compostos úteis como inibidores de metaloproteinases - Google Patents

Compostos úteis como inibidores de metaloproteinases

Info

Publication number
BR0312615A
BR0312615A BR0312615-3A BR0312615A BR0312615A BR 0312615 A BR0312615 A BR 0312615A BR 0312615 A BR0312615 A BR 0312615A BR 0312615 A BR0312615 A BR 0312615A
Authority
BR
Brazil
Prior art keywords
compounds useful
metalloproteinase inhibitors
alkenyl
compound
useful
Prior art date
Application number
BR0312615-3A
Other languages
English (en)
Inventor
Burrows
Jeremy
Nicholas
Tucker
Howard
Brown
Simon
James
Patel
Ian
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0312615A publication Critical patent/BR0312615A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

"COMPOSTOS úTEIS COMO INIBIDORES DE METALOPROTEINASES". A presente invenção se refere a um composto de fórmula (1), onde B é C~ 2~-~ 4~-alquenila ou C~ 2~-~ 4~-alquinila opcionalmente substituídos; o referido composto é de utilidade no processo de inibição de uma ou mais metaloproteinases, em particular da TACE.
BR0312615-3A 2002-07-13 2003-07-09 Compostos úteis como inibidores de metaloproteinases BR0312615A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0216382.2A GB0216382D0 (en) 2002-07-13 2002-07-13 Compounds
PCT/GB2003/002985 WO2004006927A2 (en) 2002-07-13 2003-07-09 Sulphonylpiperidine derivatives containing an alkenyl or alkynly moiety for use as matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
BR0312615A true BR0312615A (pt) 2005-04-19

Family

ID=9940462

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312615-3A BR0312615A (pt) 2002-07-13 2003-07-09 Compostos úteis como inibidores de metaloproteinases

Country Status (16)

Country Link
US (1) US20060063783A1 (pt)
EP (1) EP1531821A2 (pt)
JP (1) JP2006502990A (pt)
CN (1) CN1668302A (pt)
AU (1) AU2003246933A1 (pt)
BR (1) BR0312615A (pt)
CA (1) CA2492251A1 (pt)
GB (1) GB0216382D0 (pt)
IL (1) IL166011A0 (pt)
IS (1) IS7656A (pt)
MX (1) MXPA05000517A (pt)
NO (1) NO20050764L (pt)
PL (1) PL375361A1 (pt)
RU (1) RU2004139043A (pt)
WO (1) WO2004006927A2 (pt)
ZA (1) ZA200500210B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60230781D1 (en) 2001-09-07 2009-02-26 Kaken Pharma Co Ltd Reverse hydroxamsäurederivate
EP2041181B1 (en) * 2006-06-08 2011-05-18 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Specific protease inhibitors and their use in cancer therapy
DK2597084T3 (en) * 2010-07-08 2016-08-15 Kaken Pharma Co Ltd N-HYDROXYFORMAMIDE DERIVATIVE AND MEDICINAL CONTAINING SAME
KR101836547B1 (ko) * 2010-09-17 2018-04-19 고쿠리츠다이가쿠호우진 도쿄다이가쿠 혈소판의 기능을 유지하기 위한 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9814147A (pt) * 1997-11-12 2000-10-03 Darwin Discovery Ltd "derivados de ácido carboxìlico e hidroxâmico tendo atividade inibitória de mmp e tnf"
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
HUP0200119A3 (en) * 1999-02-08 2003-04-28 G D Searle & Co Chicago Sulfamato hydroxamic acid metalloprotease inhibitor

Also Published As

Publication number Publication date
EP1531821A2 (en) 2005-05-25
CN1668302A (zh) 2005-09-14
ZA200500210B (en) 2005-11-02
JP2006502990A (ja) 2006-01-26
IS7656A (is) 2005-01-20
US20060063783A1 (en) 2006-03-23
IL166011A0 (en) 2006-01-15
WO2004006927A3 (en) 2004-03-25
WO2004006927A2 (en) 2004-01-22
NO20050764L (no) 2005-02-11
MXPA05000517A (es) 2005-03-23
PL375361A1 (en) 2005-11-28
RU2004139043A (ru) 2005-10-10
AU2003246933A1 (en) 2004-02-02
GB0216382D0 (en) 2002-08-21
CA2492251A1 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
BR0207985A (pt) Inibidores de metaloproteinase
BR0207984A (pt) Inibidores de metaloproteinase
BR0207278A (pt) Derivados de ftalazinona-piperidina como inibidores de pde4
BRPI0615223A2 (pt) inibidores das serina proteases
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
ATE423122T1 (de) Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
BR0309556A (pt) Inibidores de metaloproteinase pirimidina-2,4,6-triona
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20061793L (no) 1,4-disubstituerte isoquinilonderlvater som RAF-kinaseinhibitorer nyttige for behandling av proliferative sykdommer
DK1485359T3 (da) Natriumkanalblokkere
MX2009009540A (es) Inhibidores de metaloproteasa que contienen una porcion heterociclica.
EA200801607A1 (ru) Производные бензимидазолонкарбоновой кислоты
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
NO20054970L (no) Arylsubstituerte byrazolforbindelser anvendbare som kinaseinhibitorer
BRPI0413973A (pt) compostos
DE502005008057D1 (de) Substituierte cyclopenten-verbindungen
NO20054787D0 (no) Indenderivater som farmasotiske midler
ATE553077T1 (de) Peptidaseinhibitoren
ATE501103T1 (de) Organische verbindungen
ATE495158T1 (de) Substituierte tetrahydroisochinoline als mmp- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament
BR0313969A (pt) Inibidores de oxitocina
TNSN05277A1 (en) Novel bioisosteres of actinonin
BRPI0512558A (pt) compostos quìmicos
BRPI0511323A (pt) tetraidroisoquinolinas substituìdas usadas na forma de inibidores de mmp, método para a produção e uso das mesmas na forma de drágeas
ATE443044T1 (de) Tace inhibitoren

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]